Lovastatin Articles
Analysts Forecast Bright Outlook For US Majors
8 April 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
FDA Issues Talk Paper On Posicor Interactions
2 January 1998
News In Brief
11 December 1997
Mevacor Study May Extend Lipid-Lowering Therapy
13 November 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
Merck's Sales Up 19% Amid Fears For The Future
17 October 1997
FDA Says Cholestin Is A Drug, Not A Supplement
17 October 1997
New Studies At European Cardiology Meeting
15 September 1997
Lipobay Selected For Large UK Study In Diabetics
24 June 1997
Forex Impacts Sales At Pfizer, Merck And S-P
22 April 1997
Court Battle Over For Apotex And Merck
4 April 1997
Lipitor To Drive Outperformance At W-L?
14 March 1997
Strong Earnings Continue At Major US Drug Firms
10 February 1997
Atorvastatin: 1st Approvals In UK And Germany
9 December 1996
Meta-Analysis Finds Statins Cut Stroke
25 November 1996
Statins Market In Europe Set For Growth, IMS Study Forecasts
23 September 1996
Fluvastatin Shows Greater Cost Benefits
29 July 1996
US Drug Majors See 2nd-Half Double-Digit Growth
29 July 1996
Tactical Diversity In The Evolving US Health Market
17 June 1996
Pipeline Contains Two Blockbusters, Says W-L
22 April 1996
Losec "Will Be The World's Top-Selling Drug In 2000"
26 February 1996
cholesterol-lowering agents implicated as carcinogens
15 January 1996
Apotex/Novopharm Lovastatin Trial To Reopen
8 January 1996
US FTC "Must Monitor Company/PBM Deals"
20 November 1995
Novopharm Guilty Of Stealing Secrets
18 September 1995
Merck & Co Sues FDA, PTO Over GATT Ruling
14 August 1995
US Sales of Generic Drugs Up 29% In 1994, Says IMS
17 July 1995
The ABPI's A-Z Of British Medicines Research
29 May 1995
Disease ManagementThe Way Forward
15 May 1995
Pravachol Label Change Reveals MI Benefit
24 April 1995
20 Leading US Drugs' Price Increases Slammed
27 March 1995
Atorvastatin Treatment IND Approved
13 March 1995
Hyperlipidemia Market Poised For Expansion
14 November 1994
USA's Top-Selling Drugs In 1993
24 October 1994
Hoechst Streamlines R&D: Update On Early Pipeline
10 October 1994
Lovastatin In Phase II Study Versus Glioma
12 September 1994
Benefits From PBM/MPC Acquisitions Assessed
15 August 1994
Strong Gains By US Firms In 2nd Quarter
1 August 1994
MERCK/SANDOZ VIE FOR MARKET SHARE
27 June 1994
MERCK & CO POSTS 10% PR0FIT RISE
25 April 1994
NEW YORK STOCK COMMENT
4 April 1994
MERCK & CO FIGHTS BACK OVER LESCOL
4 April 1994
TOKYO STOCK COMMENT
28 March 1994
PRICE WAR LOOMING FOR HYPOLIPEMICS
28 March 1994
JAPAN PHARMA MARKET IS LARGE, POOR PERFORMER
14 March 1994
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
TANABE AND SANDOZ IN DRUG ALLIANCE
2 August 1993
US PRESCRIBING TRENDS IN MARCH
28 June 1993
US DRUGMAKERS AND "THE BLACK HOLE"
21 June 1993
ATHEROSCLEROSIS AND CHOLESTEROL
31 May 1993
LOVASTATIN AND CHOLESTEROL
3 May 1993
EUROPE STOCK COMMENT
26 April 1993
PRICE FLEXIBILITY AND THE DRUG INDUSTRY
12 April 1993
JOB CUTS AND EARNINGS WARNING FROM MERCK
5 April 1993
MERCK CUTS PRICE OF TWO DRUGS
29 March 1993
XENOVA IN CLINIC WITHIN 12 TO 18 MONTHS?
8 March 1993
MERCK CANADA MOVES TO WARD OFF COMPETITION
1 March 1993
ROYAL ASSENT FOR CANADA'S PATENT REFORM
15 February 1993
GLOBAL DRUG MARKET: 30 YEARS OF GROWTH
4 January 1993
MERCK & CO EARNINGS ESTIMATES LOWERED
14 December 1992
ZANTAC TOPS MAIL ORDER SALES IN USA
8 June 1992
MERCK CLAIMS EFFICACY ADVANTAGE FOR STATINS
1 June 1992
MARS STUDY REVEALS NEW REGRESSION DATA
25 May 1992
LIPID-LOWERING OF BENEFIT IN CANCER?
18 May 1992
GOOD SALES GROWTH FOR MAJOR US COS IN 1st QTR
27 April 1992
US PRESCRIPTION PRICES UP 8.1%IN 1991
23 March 1992
MEVACOR WORKS IN FDB, SAYS STUDY
16 March 1992
VOLUME GROWTH FOR US DRUGMAKERS
9 March 1992
MERCK AFFIRMS SAFETY of MEVACOR
9 March 1992
MS&D GREECE SALES RISE 19%
3 February 1992
DECEMBER US APPROS REVIEWED
20 January 1992
EC PLENARY SESSION DECISIONS
6 January 1992
SB JOINS MERCK TO MARKET ZOCOR
6 January 1992
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
